Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presenceNext-generation ...
New research presented at ASCO GI positions both agents as potent therapeutic options, with potential to redefine standard ...
We’re starting to understand more that endometrial cancer harbors a number of cell surface markers, including folate receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback